Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation
PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX100 will be highlighted in a podium presentation at the European Society for Coloproctology (ESCP) Scientific Conference to be held on September 21-23, 2022, in Dublin, Ireland.
European Society for Coloproctology Scientific Conference:
Title: | D-PLEX100, a novel doxycycline formulation that provides high, local concentrations of antibiotic activity for 30 days to reduce surgical site infections |
Presenter: | Anthony J. Senagore, M.D., Senior Medical Director, PolyPid |
Date: | Wednesday, September 21, 2022, part of the Modern Colorectal Surgeon session |
The abstract will be available on www.polypid.com/publications/ following the presentation.
https://finance.yahoo.com/news/polypid-announces-presentation-phase-2-110000572.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.